Androgen receptor as a therapeutic target for androgen independent prostate cancer.
Androgen receptor as a therapeutic target for androgen independent prostate cancer.
复制标题
DOI：
10.1097/00045391-200603000-00013
复制
发表时间：
2006-03-01
影响因子：
4.2
通讯作者：
Farrar, William L
中科院分区：
文献类型：
--
作者：
Sharifi, Nima;Farrar, William L
前列腺癌是非皮肤恶性肿瘤的主要原因，也是男性癌症死亡的第二大原因。雄激素剥夺治疗是晚期前列腺癌的一线全身治疗。所有晚期前列腺癌最终都会生长，尽管睾丸激素水平达到去势水平。我们回顾的证据表明，雄激素非依赖性前列腺癌仍然需要雄激素受体活性的增长，雄激素受体激活的机制，在去势设置，和可能的干预点的新疗法靶向雄激素受体和前列腺癌。
Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.